Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226700 · ClinicalTrials.gov registry record · Phase 3
Suzetrigine in Total Hip Arthroplasty
A Phase 3 study of Pain and Pain Management, sponsored by Hospital for Special Surgery, New York.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
- 1
- Study location
NCT07226700 is a Phase 3 study of Pain and Pain Management that is actively recruiting participants, run by Hospital for Special Surgery, New York. The registered enrollment target is 210 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07226700, a Phase 3 study of Pain and Pain Management, is actively recruiting participants, sponsored by Hospital for Special Surgery, New York.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
- 1
- Study location
Study Summary
Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Suzetrigine
Study Locations (1)
New York
- Hospital for Special Surgery - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07226700
The ClinicalTrials.gov registry entry for NCT07226700 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 374 other Pain trials with a reported enrollment target (31% lower). The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07226700 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07226700 about?
NCT07226700 is a clinical study titled "Suzetrigine in Total Hip Arthroplasty". Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sed...
What is the current status of trial NCT07226700?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2025-11-03. Estimated completion is 2028-11-01.
What conditions does trial NCT07226700 study?
This clinical trial studies the following conditions: Pain, Pain Management, Total Hip Arthroplasty (THA), Total Hip Replacement, Total Hip Replacement Surgery.
What interventions are being tested in trial NCT07226700?
The interventions under investigation include: Placebo (OTHER), Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT07226700?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226700 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
-
Protocolized vs Discretionary Use of Opioids in Acute Pain
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.